Literature DB >> 10352163

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.

J C Learmont1, A F Geczy, J Mills, L J Ashton, C H Raynes-Greenow, R J Garsia, W B Dyer, L McIntyre, R B Oelrichs, D I Rhodes, N J Deacon, J S Sullivan.   

Abstract

BACKGROUND AND METHODS: The Sydney Blood Bank Cohort consists of a blood donor and eight transfusion recipients who were infected before 1985 with a strain of human immunodeficiency virus type 1 (HIV-1) with a deletion in the region in which the nef gene and the long terminal repeat overlap. Two recipients have died since 1994, at 77 and 83 years of age, of causes unrelated to HIV infection; one other recipient, who had systemic lupus erythematosus, died in 1987 at 22 years of age of causes possibly related to HIV. We present longitudinal immunologic and virologic data on the six surviving members and one deceased member of this cohort through September 30, 1998.
RESULTS: The five surviving recipients remain asymptomatic 14 to 18 years after HIV-1 infection without any antiretroviral therapy; however, the donor commenced therapy in February 1999. In three recipients plasma concentrations of HIV-1 RNA are undetectable (<200 copies per milliliter), and in two of these three the CD4 lymphocyte counts have declined by 9 and 30 cells per cubic millimeter per year (P=0.3 and P=0.5, respectively). The donor and two other recipients have median plasma concentrations of HIV-1 RNA of 645 to 2850 copies per milliliter; the concentration has increased in the donor (P<0.001). The CD4 lymphocyte counts in these three cohort members have declined by 16 to 73 cells per cubic millimeter per year (P<0.001). In the recipient who died after 12 years of infection, the median plasma concentration of HIV-1 RNA was 1400 copies per milliliter, with a decline in CD4 lymphocyte counts of 17 cells per cubic millimeter per year (P=0.2).
CONCLUSIONS: After prolonged infection with this attenuated strain of HIV-1, there is evidence of immunologic damage in three of the four subjects with detectable plasma HIV-1 RNA. The CD4 lymphocyte counts appear to be stable in the three subjects in whom plasma HIV-1 RNA remains undetectable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352163     DOI: 10.1056/NEJM199906033402203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  110 in total

1.  Live attenuated vaccine trials in medically informed volunteers: a special case?

Authors:  A J Pinching
Journal:  J Med Ethics       Date:  2000-02       Impact factor: 2.903

Review 2.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

4.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication.

Authors:  D Camerini; H P Su; G Gamez-Torre; M L Johnson; J A Zack; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia.

Authors:  Melissa J Churchill; Anna Figueiredo; Daniel Cowley; Lachlan Gray; Damian Fj Purcell; John S Sullivan; Dale A McPhee; Steven L Wesselingh; Bruce J Brew; Paul R Gorry
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

7.  HIV-1 vaccine development: progress and prospects.

Authors:  Anna R Thorner; Dan H Barouch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

8.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles.

Authors:  Michael Schindler; Stephanie Würfl; Philippe Benaroch; Thomas C Greenough; Rod Daniels; Philippa Easterbrook; Matthias Brenner; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 10.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.